CapsoVision, Inc Research and Development Expense
CapsoVision, Inc (CV) reported Research and Development Expense of $5.31 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- CapsoVision, Inc research and development expense for the quarter ending 2026-06-30 was $5.31M, a 56.52% increase year-over-year.
- CapsoVision, Inc research and development expense for the quarter ending 2026-03-31 was $4.43M, a 42.74% increase year-over-year.
- CapsoVision, Inc research and development expense for the quarter ending 2025-12-31 was $5.72M, a 83.60% increase year-over-year.
- CapsoVision, Inc research and development expense for the quarter ending 2025-09-30 was $6.09M, a 34.67% increase year-over-year.
- CapsoVision, Inc research and development expense for fiscal 2025 was $18.31M, a 21.10% increase from fiscal 2024.
- CapsoVision, Inc research and development expense for fiscal 2024 was $15.12M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.31M 10-Q · filed 2026-08-13 | $9.74M 10-Q · filed 2026-08-13 | $15.46M derived: sum of 3 quarters · filed 2026-08-13 | $21.55M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $4.43M 10-Q · filed 2026-05-14 | $10.16M derived: sum of 2 quarters · filed 2026-05-14 | $16.25M derived: sum of 3 quarters · filed 2026-05-14 | $19.64M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $5.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $11.81M derived: sum of 2 quarters · filed 2026-03-26 | $15.20M derived: sum of 3 quarters · filed 2026-08-13 | $18.31M 10-K · filed 2026-03-26 |
| 2025-09-30 | $6.09M 10-Q · filed 2025-11-13 | $9.48M derived: sum of 2 quarters · filed 2026-08-13 | $12.59M 10-Q · filed 2025-11-13 | $15.71M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $3.39M 10-Q · filed 2026-08-13 | $6.50M 10-Q · filed 2026-08-13 | $9.62M derived: sum of 3 quarters · filed 2026-08-13 | $14.14M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $3.11M 10-Q · filed 2026-05-14 | $6.22M derived: sum of 2 quarters · filed 2026-05-14 | $10.74M derived: sum of 3 quarters · filed 2026-05-14 | $14.97M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $7.64M derived: sum of 2 quarters · filed 2026-03-26 | $11.86M derived: sum of 3 quarters · filed 2026-03-26 | $15.12M 10-K · filed 2026-03-26 |
| 2024-09-30 | $4.52M 10-Q · filed 2025-11-13 | $8.74M derived: sum of 2 quarters · filed 2025-11-13 | $12.00M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $4.22M 10-Q · filed 2025-08-14 | $7.48M 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B | |
| Nexalin Technology, Inc. (NXL) | United States | $0.094B | |
| Streamex Corp. (STEX) | United States | $0.089B | -0.19 |
| Outset Medical, Inc. (OM) | United States | $0.059B | -1.09 |
| PRECISION OPTICS CORPORATION, INC. (POCI) | United States | $0.052B |